Novonesis AS — Director's Dealing 2012

Sep 12, 2012

September 12, 2012

In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes to 7.64%, previously reported at 7.82% (a decrease of 0.18%).

Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 24,845,307 shares of a nominal value of DKK 49,690,614, equivalent to 7.64% of Novozymes A/S' share capital and 3.07% of the voting rights. The announcement is a result of Baillie Gifford Overseas Limited, a wholly owned subsidiary of Baillie Gifford & Co, decreasing its holding of B shares in Novozymes A/S to a total of 16,235,029 B shares of a nominal value of DKK 32,470,058, equivalent to 4.995% of Novozymes share capital.

Contact persons: Press and media: Investor relations: René Tronborg (Europe) Tel. (direct): +45 4446 2274 Tel. (mobile): +45 3077 2274

Paige Donnelly (USA) Tel. (direct): +1 919 494 3209 Tel. (mobile): +1 919 218 4501

Maarit Pokkinen Tel. (direct): +45 4446 8682 Tel. (mobile): +45 3077 8682

Martin Riise Tel. (direct): +45 4446 0738 Tel. (mobile): +45 3077 0738

Thomas Bomhoff (USA) Tel. (direct): +1 919 494 3483 Tel. (mobile): +1 919 649 2565

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.

Krogshoejvej 36 2880 Bagsvaerd Denmark

Telephone: +45 4446 0000 Fax: +45 4446 9999 Internet: www.novozymes.com CVR number: 10 00 71 27